# Sabra Health Care REIT, Inc. (SBRA)

> Source: Nexqual · https://nexqual.com/SBRA · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Sabra Health Care REIT, Inc. (SBRA), nexqual.com/SBRA" · informational, not investment advice.

**Price:** USD 19.6 (+3.70% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 18.9 · day 18.88–19.66 · 52w 17.17–22.77 · market cap $5.01B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $860M, net income $65.4M (7.6% margin) (SEC filings).
- Valuation: P/E 76.5x (avg 101.2x at the last 3 fiscal year-ends), net debt $2.39B.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $4.2M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.56 on a 1–5 scale) (16 analysts), mean target USD 22.36 (range 19–25).
- Total return with dividends: 1Y +14.3% vs S&P 500 +14.9%; 5Y +93.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-02, EPS estimate USD 0.17, revenue estimate $236M.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $570M | $625M | $648M | $703M | $775M | $860M |
| Net income | -$113M | -$77.6M | $13.8M | $127M | $156M | $65.4M |
| EPS (diluted) | -$0.52 | -$0.34 | $0.06 | $0.54 | $0.64 | — |
| Net margin | -19.9% | -12.4% | 2.1% | 18.0% | 20.1% | 7.6% |
| Revenue growth | -4.8% | +9.7% | +3.6% | +8.6% | +10.2% | — |
| Cash + short-term investments | $112M | $49.3M | $41.3M | $60.5M | $71.5M | — |
| Total debt | $2.39B | $2.51B | $2.41B | $2.42B | $2.53B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 76.5x · P/S 5.8x · EV/Sales 8.6x · P/B 1.8x · Earnings yield 1.31% · Dividend yield (paid, TTM) 5.95% · Net debt $2.39B · EV $7.40B
P/E at fiscal year-ends: Dec 2025 29.8x, Dec 2024 32.3x, Dec 2023 241.5x.

## Insider sales (SEC Form 4, open-market, last ~7 months)
1 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Matros Richard K | Chair, CEO and President | 200,000 | $4.2M | 7.1% | Yes (adopted June 8, 2026) | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

## Analysts
Consensus Hold (mean 2.56 on a 1–5 scale), 16 analysts; mean target USD 22.36 (low 19, high 25).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | Wells Fargo | Target lowered | Overweight | $23 → $21 |
| 2026-10-13 | UBS | Target lowered | Neutral | $21 → $20 |
| 2026-10-13 | Barclays | Target lowered | Equal-Weight | $23 → $21 |
| 2026-08-31 | Barclays | Target raised | Equal-Weight | $21 → $23 |
| 2026-08-31 | Baird | Target raised | Neutral | $20 → $21 |
| 2026-08-06 | Raymond James | Upgrade | Underperform → Market Perform |  |
| 2026-07-22 | Baird | Target raised | Neutral | $22 → $23 |
| 2026-07-22 | Truist Securities | Target raised | Buy | $22 → $24 |
| 2026-07-22 | Citizens | Target raised | Market Outperform | $23 → $25 |
| 2026-07-08 | UBS | Target lowered | Neutral | $22 → $21 |
| 2026-07-08 | Truist Securities | Upgrade | Hold → Buy | $22 |
| 2026-07-07 | Barclays | Initiated | Equal-Weight | $21 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +14.3% | +93.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +14.4% | +14.1% |
| Volatility (annualized) | 24.6% | 24.8% |
| Max drawdown | -16.1% (May 2026→Jun 2026) | -32.5% (Aug 2022→Mar 2023) |

## Peers (REIT - Healthcare Facilities)
HR (Healthcare Realty Trust Incorpo) USD 17.93 +4.00% · NHI (National Health Investors, Inc.) USD 66.96 +3.14% · CTRE (CareTrust REIT, Inc.) USD 36.62 +2.72% · LTC (LTC Properties, Inc.) USD 43.33 +2.70% · AHR (American Healthcare REIT, Inc.) USD 53.4 +1.02% · DHC (Diversified Healthcare Trust) USD 7.87 +2.34%

## More
Full page: https://nexqual.com/SBRA · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Company outlook (8-K filed 2026-08-03)

- "REITERATES 2026 GUIDANCE TUSTIN, CA, August 3, 2026 — Sabra Health Care REIT, Inc."
- "The dividend will be paid on August 31, 2026, to common stockholders of record as of the close of business on August 14, 2026. • Sabra is also reiterating its full year 2026 guidance, which was included in Sabra's July 21, 2026, business update."

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.17 | $0.17 | -2.9% | $236.4M | 2 |
| Next quarter (ends 2026-12-31) | $0.18 | $0.17 | +1.9% | $243.3M | 3 |
| Current fiscal year (ends 2026-12-31) | $0.40 | $0.69 | -41.2% | $926.5M | 8 |
| Next fiscal year (ends 2027-12-31) | $0.81 | $0.74 | +9.0% | $1.02B | 2 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-11-20 (includes earnings 2026-11-02): ±6.4%; last 8 reports averaged ±2.4%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-11-20 | 28 | 24.3% | ±6.4% |
| 2026-12-18 | 56 | 22.9% | ±7.7% |
| 2027-01-15 | 84 | 21.1% | ±8.5% |
| 2027-04-16 | 175 | 30.9% | ±17.2% |